Roche builds “best research center in the world”
The pharmaceutical giant Roche has officially started building its new research center in Basel. Around 1,800 researchers should be able to work there by the end of 2023.
This is what Roche's new research center will look like (Visualization: Roche)
Roche has laid the foundation for its new research center (pRED Innovation Center) in Basel. A state-of-the-art laboratory and office environment will be completed by the end of 2023 at the company headquarters, providing space for about 1,800 researchers.
According to Roche’s own information, it is investing CHF 3 billion in development at the Basel site overall. From this, around CHF 1.2 billion will be put towards the new research center alone, which will comprise four new buildings. This investment is said to be a clear commitment to Switzerland as a location for research and business. Jürg Erismann, Head of the Basel/Kaiseraugst site at Roche, is quoted in an article by SRF, saying: “We are building the best research center in the world.” In the press release from Roche, he adds that the work environment being created can adapt to the changing requirements of the research division and digitization.
Sustainability is particularly important in constructing the new buildings; for instance, recycled concrete is being used to create the shell. Solar power systems will also be installed on the roofs of two buildings.
Share this article
You might also be interested in
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More
Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.Read More
Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.Read More
The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.Read More